<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Front Vet Sci</journal-id><journal-id journal-id-type="publisher-id">Front. Vet. Sci.</journal-id><journal-title-group><journal-title>Frontiers in Veterinary Science</journal-title></journal-title-group><issn pub-type="epub">2297-1769</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40400665</article-id><article-id pub-id-type="pmc">PMC12094042</article-id><article-id pub-id-type="doi">10.3389/fvets.2025.1574794</article-id><article-categories><subj-group subj-group-type="heading"><subject>Veterinary Science</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Evaluation of two commercial IBR marker vaccines against <italic>Bubaline alphaherpesvirus 1</italic> in water buffalo (<italic>Bubalus bubalis</italic>)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Cappelli</surname><given-names>Giovanna</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2548278/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Petrini</surname><given-names>Stefano</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1011423/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Grandoni</surname><given-names>Francesco</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/968707/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Grassi</surname><given-names>Carlo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1009793/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>De Donato</surname><given-names>Immacolata</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/></contrib><contrib contrib-type="author"><name><surname>Signorelli</surname><given-names>Federica</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2186695/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Napolitano</surname><given-names>Francesco</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2907517/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Vecchio</surname><given-names>Roberta</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Balestrieri</surname><given-names>Anna</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1932986/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>De Carlo</surname><given-names>Esterina</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2758157/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>De Matteis</surname><given-names>Giovanna</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1017498/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Martucciello</surname><given-names>Alessandra</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/990783/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>National Reference Centre on Water Buffalo Farming and Productions Hygiene and Technologies (CReNBuf), Istituto Zooprofilattico Sperimentale del Mezzogiorno</institution>, <addr-line>Portici</addr-line>, <country>Italy</country></aff><aff id="aff2"><sup>2</sup><institution>National Reference Centre for Infectious Bovine Rhinotracheitis (IBR), Istituto Zooprofilattico Sperimentale Umbria-Marche &#x0201c;Togo Rosati&#x0201d;</institution>, <addr-line>Perugia</addr-line>, <country>Italy</country></aff><aff id="aff3"><sup>3</sup><institution>Research Centre for Animal Production and Aquaculture, Consiglio per la Ricerca in Agricoltura e l&#x02019;Analisi dell&#x02019;Economia Agraria (CREA)</institution>, <addr-line>Monterotondo</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by" id="fn0002"><p>Edited by: Maxim C.-J. Cheeran, University of Minnesota Twin Cities, United States</p></fn><fn fn-type="edited-by" id="fn0003"><p>Reviewed by: Mirinda Van Kleef, Agricultural Research Council of South Africa (ARC-SA), South Africa</p><p>Laxmi Narayan Sarangi, National Dairy Development Board, India</p></fn><corresp id="c001">*Correspondence: Giovanna Cappelli, <email>giovanna.cappelli@izsmportici.it</email></corresp><fn fn-type="equal" id="fn0001"><p><sup>&#x02020;</sup>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1574794</elocation-id><history><date date-type="received"><day>11</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Cappelli, Petrini, Grandoni, Grassi, De Donato, Signorelli, Napolitano, Vecchio, Balestrieri, De Carlo, De Matteis and Martucciello.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Cappelli, Petrini, Grandoni, Grassi, De Donato, Signorelli, Napolitano, Vecchio, Balestrieri, De Carlo, De Matteis and Martucciello</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The present study aimed to evaluate two commercial infectious bovine rhinotracheitis (IBR) marker vaccines against <italic>Bubaline alphaherpesvirus 1</italic> (BuAHV-1) in water buffalo <italic>(Bubalus bubalis)</italic>. Thirteen water buffaloes seronegative to Bovine alphaherpesvirus 1 (BoAHV-1) and BuAHV-1 were selected and divided into three groups (VAX-1, VAX-2, CNT). VAX-1 received an IBR marker (gE-/tk-) live vaccine; VAX-2 received an IBR marker (gE-) inactivated vaccine; CNT represented the controls. Two injections of 2&#x0202f;mL each were administered 21&#x0202f;days apart. On 55 post-vaccination days (PVDs), all animals were challenged infected with wild-type BuAHV-1. Nasal swabs and serum samples were collected at different experimental times and were used for virological, serological and immunological investigations. After seven post-challenge days (PCDs), only the CNT evidenced nasal mucus discharge and increased rectal temperature. The glycoprotein B (gB) of BoAHV-1 positivity was detected using Real-time PCR from PCDs 2 to 7 in vaccinated groups. In the controls, gB positivity was detected from PCD 2 to 15. On PVD 34, all vaccinated animals progressively increased their neutralizing antibody (NA) titers statistically until the end of the experiments. In the controls, the NAs appeared on PCD 10. Flow cytometric analysis of lymphocyte populations revealed that BuAHV-1 activates adaptive immune responses. Throughout the entire examination period, both vaccinated and unvaccinated animals exhibited similar trends. However, significant differences were observed at specific time points in the CD4<sup>+</sup>, CD8<sup>+</sup>, and &#x003b3;&#x003b4; T lymphocyte subsets between the vaccinated groups and control group. These findings suggested that the IBR marker vaccines tested in this study could be used to protect the water buffalo against BuAHV-1.</p></abstract><kwd-group><kwd>water buffalo</kwd><kwd>IBR</kwd><kwd>marker vaccines</kwd><kwd>BoAHV-1</kwd><kwd>BuAHV-1</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. The funding for this research was provided by RC IZS ME 12/20 RC, Financed by the Italian Ministry of Health.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="6"/><equation-count count="1"/><ref-count count="37"/><page-count count="11"/><word-count count="8013"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Veterinary Infectious Diseases</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>Introduction</title><p>In Italy, water buffalo (<italic>Bubalus bubalis</italic>) is zootechnically and economically relevant in connection with a typical renowned product, Mozzarella di Bufala Campana (<xref rid="ref1" ref-type="bibr">1</xref>). This species is mainly reared in southern Italy, particularly in the Campania Region, with an animal population of 305,023 heads (<xref rid="ref2" ref-type="bibr">2</xref>). Water buffaloes and cattle (<italic>Bos taurus</italic>) are closely related species as they belong to the same family, <italic>Bovidae</italic>. However, they belong to different genera, which highligths their dissimilarities. Thus, research on cattle cannot be applied to water buffaloes without proper verification. The susceptibility of hosts to different herpesviruses has somehow changed over the years. Both water buffaloes and cattle are now known to be susceptible to both <italic>Bovine alphaherpesvirus 1</italic> (BoAHV-1) and <italic>Bubaline alphaherpesvirus 1</italic> (BuAHV-1) (<xref rid="ref3" ref-type="bibr">3</xref>). These viruses have gone through a process of &#x0201c;adaptation&#x0201d; to ensure a higher survival rate in the environment, even after a latent infection. The contagion occurs horizontally and vertically (<xref rid="ref4" ref-type="bibr">4</xref>), causing both direct (clinical or subclinical disease) and indirect (infertility, decreased milk production, abortion, encephalitis) health damages in animals. The infection explains why IBR is a disease of great economic importance in many parts of the world, particularly in Europe (<xref rid="ref5" ref-type="bibr">5&#x02013;10</xref>). In European countries, our IBR can negatively affect the marketing and movement of seropositive animals from one area to another (<xref rid="ref6" ref-type="bibr">6</xref>). To date, however, the cost of IBR is a missing piece of information in Europe. In one study, it was shown that inoculating 5-month-old water buffaloes with a wild-type BoAHV-1 isolated from a bovine outbreak resulted in water buffaloes being susceptible to BoAHV-1 infection (<xref rid="ref7" ref-type="bibr">7</xref>). In addition, the importance of this species as a reservoir for BoAHV-1 has been evidenced. However, the presence of BoAHV-1 in water buffaloes is not associated with the severe clinical signs usually seen in cattle infections, especially where cattle and water buffaloes are kept together on the same farm. On the contrary, different clinical signs (breathing difficulty, coughing, sneezing, wheezing, nasal and conjunctival hypersecretion, hyperthermia &#x0003e; 41&#x000b0;C, inappetence, sensory depression and lethargy) were evidenced in a study with young water buffalo calves infected with BuAHV-1. In some subjects, enteric symptoms (diarrhea) were observed and one water buffalo calf showed hair ruffling (<xref rid="ref9" ref-type="bibr">9</xref>). For these reasons and due to the lack of a specific water buffalo vaccine against IBR, the present study aimed to evaluate two commercial IBR marker vaccines against <italic>Bubaline alphaherpesvirus 1</italic> (BuAHV-1) in water buffalo <italic>(Bubalus bubalis).</italic></p></sec><sec sec-type="materials|methods" id="sec2"><label>2</label><title>Materials and methods</title><sec id="sec3"><label>2.1</label><title>IBR marker vaccines</title><p>The IBR marker vaccines used in this study were: (a) live attenuated IBR marker vaccine (gE-/tk-; VAX-1); (b) inactivated IBR marker (gE-; VAX-2). Both IBR marker vaccines were administered intranasally (i.n.), while the booster doses were injected intramuscularly (i.m.) into the neck muscle 21 days thereafter. Each vaccine was administered at a dose of 2&#x0202f;mL/head. This concentration is authorized for the bovine species. As there is no indication for the buffalo species, we used the same concentrations authorized for cattle in this study (<xref rid="tab1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>IBR marker vaccines used in the experiment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">No. of water buffaloes</th><th align="center" valign="top" rowspan="1" colspan="1">Vaccine identification</th><th align="center" valign="top" rowspan="1" colspan="1">Type</th><th align="center" valign="top" rowspan="1" colspan="1">Virus concentration TCID<sub>50</sub> in One dose (2&#x0202f;mL)</th><th align="center" valign="top" rowspan="1" colspan="1">No. of inoculation</th><th align="center" valign="top" rowspan="1" colspan="1">Inoculation route</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">Live IBR-marker vaccine (gE-/tk-)</td><td align="center" valign="top" rowspan="1" colspan="1">5 &#x000d7; 10<sup>5.50</sup> TCID<sub>50</sub>/mL</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Intranasal (first immunization)/Intramuscular (Booster)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">Inactivated IBR marker vaccine (gE-)</td><td align="center" valign="top" rowspan="1" colspan="1">5 &#x000d7; 10<sup>5.50</sup> TCID<sub>50</sub>/mL</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Intranasal (first immunization)/Intramuscular (Booster)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" colspan="4" rowspan="1">
<italic>Unvaccinated control</italic>
</td></tr></tbody></table><table-wrap-foot><p>gE, glycoprotein E of Bovine alphaherpesvirus-1; tk, thymidine-kinase enzyme of Bovine alphaherpesvirus-1; TCID<sub>50</sub>/mL, median Tissue Culture Infectious Dose.</p></table-wrap-foot></table-wrap></sec><sec id="sec4"><label>2.2</label><title>Virus</title><p>Two viruses were selected for the present study. The Sch&#x000f6;nb&#x000f6;ken strain of BoAHV-1 was used for <italic>in vitro</italic> testing. Prof. Martin Beer, Friedrich-Loeffler Institute, Greifswald, Germany, kindly provided the BoAHV-1. In addition, the wt-BuAHV-1 strain was used for <italic>in vitro</italic> and <italic>in vivo</italic> infections (<xref rid="ref11" ref-type="bibr">11</xref>) (GenBank accession No. KF679678.1). Viruses were cultured in Madin-Darby Bovine Kidney (MDBK) cells at a median tissue culture infection dose of 1.5&#x0202f;&#x000d7;&#x0202f;10<sup>8.00</sup> TCID<sub>50</sub>/mL, calculated by the Reed and Muench method (<xref rid="ref12" ref-type="bibr">12</xref>). All <italic>in vitro</italic> experiments with BuAHV-1 and BoAHV-1 cells were performed in a biosafety level 2 (BSL2) laboratory.</p></sec><sec id="sec5"><label>2.3</label><title>Experimental design</title><p>A linear model with ANOVA procedure was used to estimate the number of animals to be used. Using the variance and minimum difference obtained and assuming a significance level of 0.05 relative to a value of t&#x0202f;=&#x0202f;1.987 corresponding to 88 degrees of freedom of error, n was estimated using the formula <italic>n</italic> &#x0003e;&#x0202f;= 2 * &#x003ec;2 * (t&#x003b1;; v / d0)2. Thirteen three-month-old water buffalo calves free of neutralizing antibodies (NA) to BoAHV-1 and BuAHV-1 were selected, according to the results obtained in a previous study (<xref rid="ref13" ref-type="bibr">13</xref>). The purchased animals came from two farms in Italy, one in the Lazio Region (Central Italy) and one in the Calabria Region (Southern Italy). According to the herd&#x02019;s history, a BoAHV-1 vaccine had never been used on both farms, and no clinical symptoms that could be traced back to herpesvirus infection had ever been diagnosed. The water buffaloes were transferred to the experimental farm enclosure of the Istituto Zooprofilattico Sperimentale del Mezzogiorno (IZSM) after obtaining proper authorization (No. 202/2021-PR) under Directive 2010/63/EU on the protection of animals used for scientific purposes released from the Italian Ministry of Health. Animals in each group were housed in separate paddocks, were fed grass hay <italic>ad libitum</italic>, pelleted feed of 5&#x0202f;kg/head/day and had free access to water.</p></sec><sec id="sec6"><label>2.4</label><title>Immunization and challenge infection</title><p>The water buffaloes were divided into three groups: VAX-1, VAX-2 and CNT as unvaccinated control group. All animals were clinically examined and rectal temperature measured daily from 1 month before the immunization to 63 post-challenge days (PCDs). In addition, all animals were sampled through nasal swabs, dry and in MEM medium. Samples were collected at 0, 14, 20 and 34 post-vaccination days (PVDs) and at 0, 2, 4, 7, 10, 15, 30, and 63 PCDs. Fifty-five days after the first vaccination, all animals were challenge infected with a wild-type BuAHV-1 strain (GenBank accession number KF679678.1). The virus was injected into each animal by intranasal route at a 5 &#x000d7; 10<sup>5.50</sup> TCID<sub>50</sub>/mL dose. At 0, 2, 4, 7, 10, 15, 20, 30, and 63 PCDs, nasal swabs and serum samples were collected from all animals. Two RT-PCRs against BoAHV-1 and BuAHV-1 (see Section 2.6) were performed on nasal swab samples. In addition, ELISA tests (see Section 2.8) and virus neutralization assays (see Section 2.8) against BoAHV-1 and BuAHV-1 were performed on serum samples.</p></sec><sec id="sec7"><label>2.5</label><title>Clinical monitoring</title><p>The animals in each group were housed in separate pens with free access to food and water. The water buffaloes were clinically monitored throughout the experimental period by measuring rectal temperature and assessing their general clinical condition (presence of nasal and ocular discharge; detecting respiratory and enteric symptoms; palpating explorable lymph nodes). The clinical signs were monitored and humane endpoints (HEP) were evaluated using the &#x02018;Working paper on a severity assessment framework&#x02019; by an expert European group to assess the severity suffered by animals subjected to scientific procedures.</p></sec><sec id="sec8"><label>2.6</label><title>Virological investigations</title><p>The commercial QIA Symphony DSP Virus/Pathogen Mini Kit (Qiagen, Hilden, Germany) was used to extract viral nucleic acid from nasal swabs according to the manufacturer&#x02019;s instructions. Real-time PCR was used to amplify the highly conserved target region of the UL27 gene, which is common to all alphaherpesviruses and encodes glycoprotein B (gB) of BoAHV-1 (<xref rid="ref14" ref-type="bibr">14</xref>). All samples were tested in duplicate for analysis. Positive (IBR Los Angeles strain) and negative (PBS) controls were included in the procedure. The protocol provided the addition of an internal amplification control (<italic>&#x003b2;</italic>-actin). The sample was considered positive if the cycle threshold (Ct) was &#x02264; 45. In addition, 100&#x0202f;&#x003bc;L of each nasal swab was plated into three wells of a 24-well plastic plate (CytoOne&#x000ae; Plate; Starlab LTD, Blakelands, United Kingdom) containing monolayers of MDBK cell cultures grown in MEM. The MDBK cells were provided by the Biobank of Veterinary Resources (BVR; Brescia, Italy) and were identified as BS CL 63. After incubation for 60&#x0202f;min at 37&#x000b0;C in a 5% CO<sub>2</sub> atmosphere, 1&#x0202f;mL of MEM supplemented with 2% fetal calf serum (BioWhittaker Inc., Walkersville, MD, United States) was added to each well. As positive controls, MDBK cells infected with BuAHV-1 were used. MDBK cell cultures free of BuAHV-1 were used as negative controls. The plates were incubated for 7&#x0202f;days at 37&#x000b0;C in an atmosphere of 5% CO<sub>2</sub> and were observed daily to determine whether a cytopathic effect (CPE) occurred. Viral titers were determined by the Reed and Muench method (<xref rid="ref12" ref-type="bibr">12</xref>) and expressed as total tissue culture infectious doses (TCID<sub>50</sub>/mL).</p></sec><sec id="sec9"><label>2.7</label><title>Serological surveys</title><p>The detection of antibodies against glycoprotein B (gB) and glycoprotein E (gE) of BoAHV-1 was performed using different commercial ELISA tests (ID Screen&#x000ae; IBR gB competition, and ID Screen&#x000ae; IBR gE competition; both from Innovative Diagnostics, Grables, France). In addition, the discrimination ELISA test BoAHV-1/BuAHV-1 was used (Eradikit&#x02122; BoAHV-1-BuAHV-1 Discrimination Kit; In3Diagnostic). All data were analyzed using Microplate Manager version 6 software (Bio-Rad Laboratories S.r.l., Segrate, Italy). The results were computed according to the manufacturer&#x02019;s instructions. Virus neutralization (VN) test was carried out by applying the protocol described in the WOAH Manual of Diagnostic Tests and Vaccines (<xref rid="ref14" ref-type="bibr">14&#x02013;23</xref>). Briefly, 50&#x0202f;&#x003bc;L of 100 TCID<sub>50</sub>/ml of the virus was mixed with 50&#x0202f;&#x003bc;L of undiluted serum samples using two-fold dilutions for each serum sample. The tests with BuAHV-1 and BoAHV-1 (see Section 2.2.) were carried out in parallel and in separate working sessions. Each mixture was then dispensed into three wells of 96-well microtitre plates (Nunc&#x02122;, 96-Well Microplates Polypropylene, Thermo Scientific, Milan, Italy). After incubation at 37&#x000b0;C for 24&#x0202f;h, 30,000 MDBK cell cultures suspended in 100&#x0202f;&#x003bc;L MEM were added to each well and incubated at 37&#x000b0;C for 4&#x0202f;days. The plates were then incubated and examined for cytopathology using a tissue culture microscope (Zeiss Axiovert Vert. A1, Zeiss International, Milan, Italy). Neutralization titers were expressed as the maximum dilution that inhibited the cytopathic effect.</p></sec><sec id="sec10"><label>2.8</label><title>Hematological and flow cytometry analysis</title><p>Hematological and flow cytometry analyses were performed on whole blood samples collected from the jugular vein, respectively, into K<sub>3</sub>EDTA and Li-Heparin tubes (Vacuette&#x000ae;, Greiner Bio-One, Rome, Italy). Hematological analyses were determined by the Cell-Dyn 3,700 SL instrument (Abbott, Abbott Park, IL, United States), according to the standard operating procedure. Since the leukocyte viability, assessed by LIVE/DEAD Fixable Near-IR stain kit&#x000ae; (Thermo Fisher Scientific, Waltham, MA, United States) was always higher than 98% (data not shown), B and T lymphocyte subsets were evaluated by flow cytometry using two different multicolor panels without live/dead discrimination. To evaluate the T lymphocyte subsets, a six-color panel was performed: anti-CD3 AF647 (clone MM1a); anti-CD4 Pacif-ic Blue (clone IL-A11a); anti-CD8 PE (clone CC63), anti-CD18 Brillant Violet 510 (clone 6.7); anti-<italic>&#x003b4;</italic> chain PE-Cy7 (clone GB21a), anti-WC1 FITC (clone CC15). A two-color flow cytofluorimetric panel was used to identify B lymphocytes: anti-CD21 PE (clone LT21) and anti-CD79a APC (clone HM47). The sample staining conditions were performed as described in our previous study (<xref rid="ref13" ref-type="bibr">13</xref>). After staining, samples were immediately acquired on a CytoFLEX flow cytometer, and the post-acquisition data were analyzed by CytExpert 2.4 software (Beckman Coulter, Brea, CA, United States). The gating strategy used to identify the sub-sets of interest is described in <xref rid="fig1" ref-type="fig">Figure 1</xref>. The lymphocyte subset absolute counts were estimated by combining flow cytometric relative percentages and lymphocyte absolute count obtained by hematological analysis.</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Flow cytometric gating strategy used to identify T <bold>(A&#x02013;G)</bold> and B lymphocyte <bold>(H&#x02013;K)</bold> subsets. The gate &#x0201c;Events&#x0201d; on dot plot Time vs. FL <bold>(A)</bold> was used to exclude event burst. The gate &#x0201c;Singlets&#x0201d; (FSC-A vs. FSC-H) was used to exclude doublets <bold>(B,H)</bold>, while the gate &#x0201c;CD18<sup>+</sup>&#x0201d; (CD18 vs. SSC) was used to identify total leukocytes <bold>(C)</bold>. Applying this gate to the CD3 vs. gd T dot plot <bold>(D)</bold>, we identified the &#x003b1;&#x003b2; T (as CD3<sup>+</sup>/<italic>&#x003b4;</italic> chain<sup>&#x02212;</sup> cells, see section 2.7) and &#x003b3;&#x003b4; T lymphocyte subsets (as CD3<sup>+</sup>/&#x003b4; chain<sup>+</sup>). The gate &#x0201c;ab T&#x0201d; was applied to the CD4 vs. CD8 dot plot to identify these subsets <bold>(E)</bold>. The gate &#x0201c;gd T&#x0201d; was applied to the WC1 vs. CD8 dot plot to identify the WC1<sup>+</sup> &#x003b3;&#x003b4; T lymphocyte subset. The gate hierarchies are shown in the G box. The Time vs. FL dot plot, used to exclude event burst, is not shown for the two-color panel used for B lymphocytes <bold>(H&#x02013;K)</bold>. To identify these cells, singlet events <bold>(H)</bold> were used in the FSC vs. SSC dot plot <bold>(I)</bold> to create the gate &#x0201c;Lymphocytes&#x0201d; that applied to the dot plot CD79A vs. SSC <bold>(J)</bold> allowed us to identify total B lymphocytes as CD79a<sup>+</sup> cells. Finally, the CD21<sup>+</sup> B lymphocytes were identified in the dot plot CD21 vs. CD79A <bold>(K)</bold>.</p></caption><graphic xlink:href="fvets-12-1574794-g001" position="float"/></fig></sec><sec id="sec11"><label>2.9</label><title>Statistical examination</title><p>A logarithmic scale of base 10 was used to express mean neutralizing antibody titers. Statistically significant differences were assessed using the Shapiro&#x02013;Wilk and the non-parametric Wilcoxon-Mann&#x02013;Whitney tests. The comparison was made between:<list list-type="order"><list-item><p>Neutralizing antibodies (NAs) against BuAHV-1 between vaccination groups (VAX-1 and VAX-2) and control groups (CNT);</p></list-item><list-item><p>NAs against BoAHV-1 between vaccination groups (VAX-1 and VAX-2) and control groups (CNT).</p></list-item></list></p><p>The level of significance was set at <italic>p</italic> &#x0003c;&#x0202f;0.05.</p><p>Hematologic and flow cytometric data were analyzed using the PROC MIXED procedure of SAS 9.4 (SAS Institute Inc., Cary, CA, United States) as follows:<disp-formula id="E1">
<mml:math id="M1" overflow="scroll"><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mi mathvariant="italic">ijkl</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>&#x003bc;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">b</mml:mi><mml:mrow><mml:mi mathvariant="normal">j</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mi mathvariant="normal">ijkl</mml:mi></mml:msub></mml:math>
</disp-formula></p><p>where Y<sub>ijkl</sub> is the dependent variable; &#x003bc; is the overall mean; G<sub>i</sub> is the fixed effect of the ith group (CNT, VAX-1, and VAX-2); Dj is the fixed effect of the jth PCDs 0, 2, 4, 7, 10, 15, 30, and 63; GD<sub>ij</sub> is the fixed effect of the interaction between the ith group and jth day; b<sub>jk</sub> is the random effect of the subject within the time j (k&#x0202f;=&#x0202f;1, &#x02026;,13); and &#x003b5;<sub>ijkl</sub> is the random error. Differences were considered significant at <italic>p</italic> &#x0003c;&#x0202f;0.05.</p></sec></sec><sec sec-type="results" id="sec12"><label>3</label><title>Results</title><sec id="sec13"><label>3.1</label><title>Clinical response</title><p>During the entire vaccination period, no clinical signs or adverse reactions were observed in immunized animals. After the challenge infection, no lesions were detected in immunized animals. Only in the control group at PCDs 7&#x02013;14 four out of five water buffaloes showed nasal mucus discharge, while in one animal, a nasal mucous membrane lesion associated with mucopurulent exudate and blood was detected; in addition, in the control group, an increase in rectal temperatures with a maximum peak of 39.1&#x000b0;C was observed from 0 to 63&#x0202f;days.</p></sec><sec id="sec14"><label>3.2</label><title>Virological investigations</title><p>During the vaccination period all animals were virologically negative. On the contrary, after the challenge infection, gB positivity was detected by Real-time PCR in VAX-1 and VAX-2 groups from PCDs 2 to 7. The same positivity was observed in CNT, from PCDs 2 to 15 (<xref rid="tab2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Results obtained by gB Real-time PCR after challenge infection with wild-type BuAHV-1 strain.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Group</th><th align="center" valign="top" colspan="8" rowspan="1">Post-challenge day (PCD)</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">0<sup>*</sup></th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="center" valign="top" rowspan="1" colspan="1">4</th><th align="center" valign="top" rowspan="1" colspan="1">7</th><th align="center" valign="top" rowspan="1" colspan="1">10</th><th align="center" valign="top" rowspan="1" colspan="1">15</th><th align="center" valign="top" rowspan="1" colspan="1">30</th><th align="center" valign="top" rowspan="1" colspan="1">63</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">4^</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>PCD 0 corresponds to PVD 55; -, negative results; ^, number of water buffaloes resulting positive with a cycle threshold (Ct) equal to or less than 45.</p></table-wrap-foot></table-wrap><p>Regarding the viremia, the virus was isolated from all groups PCDs 2 to 7 (<xref rid="tab3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="tab3"><label>Table 3</label><caption><p>Results obtained by virus isolation after challenge infection with wild-type BuAHV-1 strain.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Group</th><th align="center" valign="top" colspan="8" rowspan="1">Post-challenge day (PCD)</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">0<sup>*</sup></th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="center" valign="top" rowspan="1" colspan="1">4</th><th align="center" valign="top" rowspan="1" colspan="1">7</th><th align="center" valign="top" rowspan="1" colspan="1">10</th><th align="center" valign="top" rowspan="1" colspan="1">15</th><th align="center" valign="top" rowspan="1" colspan="1">30</th><th align="center" valign="top" rowspan="1" colspan="1">63</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">4.50 (4)<sup>a,b</sup></td><td align="center" valign="top" rowspan="1" colspan="1">3.24 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">4.50 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">3.50 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">5.00 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">4.50 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">2.74 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>PCD 0 corresponds to PVD 55; -; negative results; <sup>a</sup>Reciprocal value of the negative log of the TCID<sub>50</sub>/mL (group mean value); <sup>b</sup>The number of water buffaloes from which the BuAHV-1 was isolated is shown in brackets.</p></table-wrap-foot></table-wrap></sec><sec id="sec15"><label>3.3</label><title>Serological surveys</title><p>VAX-1 group showed antibodies to gB-ELISA at PVD 14, whereas the VAX-2 group evidenced the same antibodies at PVD 34. In contrast, during the immunization period, the control group resulted negative in all ELISA tests (<xref rid="tab4" ref-type="table">Table 4</xref>). An increase in NA BoAHV-1 titers at PVD 14 in the VAX-1 group was observed. In the VAX-2 group, an increase of NA BoAHV-1 titers was detected at PVD 34. A comparison of the results for NA BuAHV-1 evidenced antibodies PVD 14 in only the VAX-1 group. At PVD 34, an increase of NA BuAHV-1 was observed in the VAX-1 and VAX-2 groups compared to the control group. In contrast, the ELISA discrimination kit Bo/Bu and gE-ELISA did not detect antibodies during the entire vaccination period. No antibody changes were observed during the entire vaccination period in the CNT group (<xref rid="tab4" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="tab4"><label>Table 4</label><caption><p>Antibody response of water buffaloes immunized against BoAHV-1 with IBR marker vaccine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Group</th><th align="left" valign="top" rowspan="2" colspan="1">Test</th><th align="center" valign="top" colspan="3" rowspan="1">Post-vaccination days (PVD)</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">0</th><th align="center" valign="top" rowspan="1" colspan="1">14</th><th align="center" valign="top" rowspan="1" colspan="1">34</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3" colspan="1">VAX-1</td><td align="left" valign="top" rowspan="1" colspan="1">gE-ELISA<sup>a</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">gB-ELISA<sup>b</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">+</td><td align="center" valign="top" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ELISA Bo/Bu<sup>c</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NA BoAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td><td align="center" valign="top" rowspan="1" colspan="1">1.88</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NA BuAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td><td align="center" valign="top" rowspan="1" colspan="1">1.58</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value NA BoAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.3333</td><td align="center" valign="top" rowspan="1" colspan="1">0.0159</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value NA BuAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.8889</td><td align="center" valign="top" rowspan="1" colspan="1">0.0159</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">VAX-2</td><td align="left" valign="top" rowspan="1" colspan="1">gE-ELISA<sup>a</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">gB-ELISA<sup>b</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">+</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ELISA Bo/Bu<sup>c</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NA BoAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.53</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NA BuAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.45</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value NA BoAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.0952</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value NA BuAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.1429</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">CNT</td><td align="left" valign="top" rowspan="1" colspan="1">gE-ELISA<sup>a</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">gB-ELISA<sup>b</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ELISA Bo/Bu<sup>c</sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NA BoAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NA BuAHV-1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;1.00</td></tr></tbody></table><table-wrap-foot><p>
<sup>aID Screen&#x000ae; IBR gB competition Innovative Diagnostics, Grables, France; bID Screen&#x000ae; IBR gE competition Innovative Diagnostics, Grables, France; cEradikit&#x02122; BoAHV-1-BuAHV-1 Discrimination Kit, In3Diagnostic; p-value indicating the significant differences in NA titer between vaccinated buffaloes and unvaccinated controls.</sup>
</p></table-wrap-foot></table-wrap><p>After challenge infection, the vaccinated groups maintained the positivity to gB-ELISA until the end of the experiments. In addition, VAX-1 and VAX-2 groups produced specific antibodies to gE-ELISA at PCD 63. Moreover, a progressive increase of NA BoAHV-1 and NA BuAHV-1 was observed until the end of the experiment. In contrast, the ELISA discrimination kit Bo/Bu detected antibodies (against BoAHV-1 and BuAHV-1) in immunization groups PCD 30, whereas PCD 15 was detected in the CNT. On the contrary, the CNT group developed antibodies to gB and gE at PCDs 10 and 15, respectively. Also, in the CNT group, NA BoAHV-1 and NA BuAHV-1 were produced at PCD 10 (<xref rid="tab5" ref-type="table">Table 5</xref>).</p><table-wrap position="float" id="tab5"><label>Table 5</label><caption><p>Antibody response of water buffaloes immunized against BoAHV-1 with IBR marker vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="2" colspan="1">Group</th><th align="center" valign="middle" rowspan="2" colspan="1">Test</th><th align="center" valign="middle" colspan="8" rowspan="1">Post-challenge day (PCD)</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">0<sup>*</sup></th><th align="center" valign="middle" rowspan="1" colspan="1">2</th><th align="center" valign="middle" rowspan="1" colspan="1">4</th><th align="center" valign="middle" rowspan="1" colspan="1">7</th><th align="center" valign="middle" rowspan="1" colspan="1">10</th><th align="center" valign="middle" rowspan="1" colspan="1">15</th><th align="center" valign="middle" rowspan="1" colspan="1">30</th><th align="center" valign="middle" rowspan="1" colspan="1">63</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="middle" rowspan="1" colspan="1">gE-ELISA<sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">gB-ELISA<sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">ELISA Bo/Bu<sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">NA BoAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.81</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41</td><td align="center" valign="middle" rowspan="1" colspan="1">3.01</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">NA BuAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.81</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41</td><td align="center" valign="middle" rowspan="1" colspan="1">2.71</td><td align="center" valign="middle" rowspan="1" colspan="1">2.71</td><td align="center" valign="middle" rowspan="1" colspan="1">3.39</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic>-value NA BoAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic>-value NA BoAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0317</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="middle" rowspan="1" colspan="1">gE-ELISA<sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">gB-ELISA<sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">ELISA Bo/Bu<sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">NA BoAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">1.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">1.81</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" rowspan="1" colspan="1">2.26</td><td align="center" valign="middle" rowspan="1" colspan="1">2.63</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">NA BuAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41</td><td align="center" valign="middle" rowspan="1" colspan="1">2.63</td><td align="center" valign="middle" rowspan="1" colspan="1">2.94</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic>-value NA BoAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1429</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic>-value NA BoAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8889</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9520</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3333</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0159</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>0.0317</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1905</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CNT</td><td align="center" valign="middle" rowspan="1" colspan="1">gE-ELISA<sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">gB-ELISA<sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">ELISA Bo/Bu<sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">NA BoAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.060</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90</td><td align="center" valign="middle" rowspan="1" colspan="1">1.44</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">NA BuAHV-1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">1.32</td><td align="center" valign="middle" rowspan="1" colspan="1">2.05</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>PCD 0 corresponds to PVD 55; <sup>a</sup>ID Screen&#x000ae; IBR gB competition Innovative Diagnostics, Grables, France; <sup>b</sup>ID Screen&#x000ae; IBR gE competition Innovative Diagnostics, Grables, France; <sup>c</sup>EradikitTM BoAHV-1-BuAHV-1 Discrimination Kit, In3Diagnostic; <italic>p</italic>-value indicating the significant differences in NA titer between vaccinated buffaloes and unvaccinated controls. Statistically significant values are in bold.</p></table-wrap-foot></table-wrap></sec><sec id="sec16"><label>3.4</label><title>Flow cytometric profiling of bubaline lymphocyte subsets during BuAHV-1 infection</title><p>Flow cytometric analysis was performed for this study to evaluate changes in B and T lymphocytes subsets in response to BuAHV-1 infection in water buffaloes vaccinated with two different marker vaccines. <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref> shows the differences in T and B lymphocytes subset between unvaccinated (CNT) and vaccinated (VAX-1 and VAX-2) groups during vaccination. In <xref rid="tab6" ref-type="table">Table 6</xref>, the measurements of each lymphocyte subset during the whole period after experimental infection are shown. In addition, in <xref rid="fig2" ref-type="fig">Figure 2</xref>, values for each subset and at each time point were compared through groups. The results of the hematologic profile during infection with BuAHV-1 of the same groups of water buffaloes were reported in a previous paper (<xref rid="ref15" ref-type="bibr">15</xref>). Flow cytometric analysis revealed that although the percentage of &#x003b1;&#x003b2; T lymphocytes decreased significantly at an early stage only in control animals, the total &#x003b1;&#x003b2; T lymphocyte count decreased also in both groups of vaccinated animals (<xref rid="tab6" ref-type="table">Table 6</xref>). At PCD 63, lower values were observed in the CNT compared to vaccinated groups (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). The percentage of CD4<sup>+</sup> &#x003b1;&#x003b2; T subsets showed a significant decrease from PCD 7 to PCD 63 for all groups, showing lower values than PCD 0. The differences were significant for all points only for the CNT group (<xref rid="tab6" ref-type="table">Table 6</xref>). No significant differences among groups were observed at each time point (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). The percentage of &#x003b1;&#x003b2; T CD8<sup>+</sup> showed a significant increase at PCD 30 for VAX 2 group, and at PCD 63 for all groups.&#x0201d; Moreover, differences between CNT and VAX-2 were observed at PCD 7 (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). The &#x003b1;&#x003b2; CD4/&#x003b1;&#x003b2; CD8 ratio showed a significant decrease between PCDs 0 and 63 (<xref rid="tab6" ref-type="table">Table 6</xref>). Regarding &#x003b3;&#x003b4; T lymphocytes, a significant decrease in the total count was observed only in the CNT group at PCDs 4, 10, and 30. As for the percentage of &#x003b3;&#x003b4; T lymphocytes, significantly lower values were noted at PCD 10 for the CNT and VAX 2 groups, at PCD 30 for the CNT and VAX 1 groups, and at PCD 63 for the CNT group (<xref rid="tab6" ref-type="table">Table 6</xref>). Compared to the CNT group, both vaccinated groups evidenced lower values at each time point (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). About B lymphocytes, no significant differences were noted in their percentage or total count across the various PCDs. However, a significant decrease in CD21<sup>+</sup> B lymphocytes was observed in the CNT group at PCD 7, 10, 15, and 30 compared to PCD 0. In the VAX 1 group, significant differences were detected at PCD 15 and 30 (<xref rid="tab6" ref-type="table">Table 6</xref>).</p><table-wrap position="float" id="tab6"><label>Table 6</label><caption><p>Comparison of percentages and absolute counts (mean &#x000b1; SEM) of lymphocyte subsets in CNT, VAX-1, and VAX-2 groups. Post-challenging values (at PCDs 2, 4, 7, 10, 15, 30 and 63) were compared to the pre-challenging values (at PCD 0) for each lymphocyte subpopulation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" colspan="9" rowspan="1">Post-challenge day (PCD)</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group</th><th align="center" valign="top" rowspan="1" colspan="1">0<sup>*</sup></th><th align="center" valign="top" rowspan="1" colspan="1">2</th><th align="center" valign="top" rowspan="1" colspan="1">4</th><th align="center" valign="top" rowspan="1" colspan="1">7</th><th align="center" valign="top" rowspan="1" colspan="1">10</th><th align="center" valign="top" rowspan="1" colspan="1">15</th><th align="center" valign="top" rowspan="1" colspan="1">30</th><th align="center" valign="top" rowspan="1" colspan="1">63</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SEM</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SEM</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SEM</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SEM</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SEM</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SEM</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SEM</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean &#x000b1; SEM</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x003b1;&#x003b2; T Lymphocytes (%)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>22.8&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>15.8&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">18.3&#x0202f;&#x000b1;&#x0202f;2.5</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>13.3&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>12.4&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>16.0&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup><bold>b</bold>-B</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>11.3&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>13.6&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">19.2&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">13.4&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">12.2&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">13.8&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">11.5&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">16.3&#x0202f;&#x000b1;&#x0202f;2.7b</td><td align="center" valign="top" rowspan="1" colspan="1">11.8&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">20.5&#x0202f;&#x000b1;&#x0202f;2.7</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">22.5&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">10.8&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">14.7&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">11.9&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">7.4&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>24.9&#x0202f;&#x000b1;&#x0202f;2.7</bold>
<sup>
<bold>a</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">11.5&#x0202f;&#x000b1;&#x0202f;2.7</td><td align="center" valign="top" rowspan="1" colspan="1">17.7&#x0202f;&#x000b1;&#x0202f;2.7</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x003b1;&#x003b2; T Lymphocytes (cells/uL)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>1,028&#x0202f;&#x000b1;&#x0202f;124</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>558&#x0202f;&#x000b1;&#x0202f;124</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">707&#x0202f;&#x000b1;&#x0202f;124<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>591&#x0202f;&#x000b1;&#x0202f;124</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>485&#x0202f;&#x000b1;&#x0202f;124</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>629&#x0202f;&#x000b1;&#x0202f;124</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>542&#x0202f;&#x000b1;&#x0202f;124</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>806&#x0202f;&#x000b1;&#x0202f;124</bold>
<sup>
<bold>b</bold>
</sup>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>1,068&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>652&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>664&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">795&#x0202f;&#x000b1;&#x0202f;139</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>597&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">741&#x0202f;&#x000b1;&#x0202f;139</td><td align="center" valign="top" rowspan="1" colspan="1">853&#x0202f;&#x000b1;&#x0202f;139</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>1,273&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>a</bold>
</sup>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>1,123&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>490&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>685&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">661&#x0202f;&#x000b1;&#x0202f;139<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>379&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">930&#x0202f;&#x000b1;&#x0202f;139</td><td align="center" valign="top" rowspan="1" colspan="1">790&#x0202f;&#x000b1;&#x0202f;139</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>1,203&#x0202f;&#x000b1;&#x0202f;139</bold>
<sup>
<bold>a</bold>
</sup>
</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x003b1;&#x003b2; T CD4<sup>+</sup> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>76.7&#x0202f;&#x000b1;&#x0202f;1.9</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">78.3&#x0202f;&#x000b1;&#x0202f;1.9</td><td align="center" valign="top" rowspan="1" colspan="1">78.5&#x0202f;&#x000b1;&#x0202f;1.9</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>69.5&#x0202f;&#x000b1;&#x0202f;1.9</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">72.7&#x0202f;&#x000b1;&#x0202f;1.9<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">72.9&#x0202f;&#x000b1;&#x0202f;1.9<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">72.9&#x0202f;&#x000b1;&#x0202f;1.9<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">72.8&#x0202f;&#x000b1;&#x0202f;1.9<sup>B</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>76.6&#x0202f;&#x000b1;&#x0202f;2.2</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">76.4&#x0202f;&#x000b1;&#x0202f;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">77.1&#x0202f;&#x000b1;&#x0202f;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">73.4&#x0202f;&#x000b1;&#x0202f;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">73.5&#x0202f;&#x000b1;&#x0202f;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">75.4&#x0202f;&#x000b1;&#x0202f;2.2</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>69.8&#x0202f;&#x000b1;&#x0202f;2.2</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">72.9&#x0202f;&#x000b1;&#x0202f;2.2</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>77.4&#x0202f;&#x000b1;&#x0202f;2.2</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">78.0&#x0202f;&#x000b1;&#x0202f;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">76.1&#x0202f;&#x000b1;&#x0202f;2.2</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>71.5&#x0202f;&#x000b1;&#x0202f;2.2</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>71.2&#x0202f;&#x000b1;&#x0202f;2.2</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">74.9&#x0202f;&#x000b1;&#x0202f;2.2</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>69.6&#x0202f;&#x000b1;&#x0202f;2.2</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">73.9&#x0202f;&#x000b1;&#x0202f;2.2</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x003b1;&#x003b2; T CD8<sup>+</sup> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>14.1&#x0202f;&#x000b1;&#x0202f;1.8</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">12.1&#x0202f;&#x000b1;&#x0202f;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">11.5&#x0202f;&#x000b1;&#x0202f;1.8</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>19.2&#x0202f;&#x000b1;&#x0202f;1.8</bold>
<sup>a-<bold>A</bold></sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">16.3&#x0202f;&#x000b1;&#x0202f;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">16.1&#x0202f;&#x000b1;&#x0202f;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">16.9&#x0202f;&#x000b1;&#x0202f;1.8</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>18.3&#x0202f;&#x000b1;&#x0202f;1.8</bold>
<sup>
<bold>A</bold>
</sup>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>13.7&#x0202f;&#x000b1;&#x0202f;2.0</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">13.5&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">12.9&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">15.8&#x0202f;&#x000b1;&#x0202f;2.0<sup>ab</sup></td><td align="center" valign="top" rowspan="1" colspan="1">14.9&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">13.9&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">18.6&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>17.3&#x0202f;&#x000b1;&#x0202f;2.0</bold>
<sup>
<bold>A</bold>
</sup>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>12.7&#x0202f;&#x000b1;&#x0202f;2.0</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">11.2&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">13.9&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">13.2&#x0202f;&#x000b1;&#x0202f;2.0<sup>b</sup></td><td align="center" valign="top" rowspan="1" colspan="1">15.2&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1">13.9&#x0202f;&#x000b1;&#x0202f;2.0</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>18.1&#x0202f;&#x000b1;&#x0202f;2.0</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">16.4&#x0202f;&#x000b1;&#x0202f;2.0<sup>A</sup></td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x003b1;&#x003b2; CD4/ &#x003b1;&#x003b2; CD8</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>5.53&#x0202f;&#x000b1;&#x0202f;1.00</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">6.62&#x0202f;&#x000b1;&#x0202f;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">7.01&#x0202f;&#x000b1;&#x0202f;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">3.70&#x0202f;&#x000b1;&#x0202f;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">4.64&#x0202f;&#x000b1;&#x0202f;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">4.82&#x0202f;&#x000b1;&#x0202f;1.00</td><td align="center" valign="top" rowspan="1" colspan="1">4.35&#x0202f;&#x000b1;&#x0202f;1.00</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>4.07&#x0202f;&#x000b1;&#x0202f;1.00</bold>
<sup>
<bold>B</bold>
</sup>
</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">6.06&#x0202f;&#x000b1;&#x0202f;1.12<sup>A</sup></td><td align="center" valign="top" rowspan="1" colspan="1">6.37&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">8.08&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">5.90&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">6.28&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">5.93&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">4.31&#x0202f;&#x000b1;&#x0202f;1.12<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">4.48&#x0202f;&#x000b1;&#x0202f;1.12<sup>B</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">6.23&#x0202f;&#x000b1;&#x0202f;1.12<sup>A</sup></td><td align="center" valign="top" rowspan="1" colspan="1">7.32&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">5.66&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">5.52&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">4.92&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">5.53&#x0202f;&#x000b1;&#x0202f;1.12</td><td align="center" valign="top" rowspan="1" colspan="1">4.46&#x0202f;&#x000b1;&#x0202f;1.12<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">4.67&#x0202f;&#x000b1;&#x0202f;1.12<sup>B</sup></td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x003b3;&#x003b4; T Lymphocytes (%)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>15.6&#x0202f;&#x000b1;&#x0202f;2.8</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">14.0&#x0202f;&#x000b1;&#x0202f;2.8<sup>a</sup></td><td align="center" valign="top" rowspan="1" colspan="1">12.6&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">16.8&#x0202f;&#x000b1;&#x0202f;2.8<sup>a</sup></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>10.1&#x0202f;&#x000b1;&#x0202f;2.8</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">16.3&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>6.7&#x0202f;&#x000b1;&#x0202f;2.8</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">11.4&#x0202f;&#x000b1;&#x0202f;2.8<sup>B</sup></td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">11.5&#x0202f;&#x000b1;&#x0202f;3.1<sup>A</sup></td><td align="center" valign="top" rowspan="1" colspan="1">11.7&#x0202f;&#x000b1;&#x0202f;3.1<sup>ab</sup></td><td align="center" valign="top" rowspan="1" colspan="1">8.6&#x0202f;&#x000b1;&#x0202f;3.1</td><td align="center" valign="top" rowspan="1" colspan="1">9.4&#x0202f;&#x000b1;&#x0202f;3.1<sup>ab</sup></td><td align="center" valign="top" rowspan="1" colspan="1">8.1&#x0202f;&#x000b1;&#x0202f;3.1</td><td align="center" valign="top" rowspan="1" colspan="1">12.6&#x0202f;&#x000b1;&#x0202f;3.1</td><td align="center" valign="top" rowspan="1" colspan="1">6.0&#x0202f;&#x000b1;&#x0202f;3.1<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">10.5&#x0202f;&#x000b1;&#x0202f;3.1</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">8.0&#x0202f;&#x000b1;&#x0202f;3.1<sup>A</sup></td><td align="center" valign="top" rowspan="1" colspan="1">5.8&#x0202f;&#x000b1;&#x0202f;3.1<sup>b</sup></td><td align="center" valign="top" rowspan="1" colspan="1">5.9&#x0202f;&#x000b1;&#x0202f;3.1</td><td align="center" valign="top" rowspan="1" colspan="1">7.8&#x0202f;&#x000b1;&#x0202f;3.1<sup>b</sup></td><td align="center" valign="top" rowspan="1" colspan="1">3.3&#x0202f;&#x000b1;&#x0202f;3.1<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">10.6&#x0202f;&#x000b1;&#x0202f;3.1</td><td align="center" valign="top" rowspan="1" colspan="1">3.8&#x0202f;&#x000b1;&#x0202f;3.1</td><td align="center" valign="top" rowspan="1" colspan="1">6.2&#x0202f;&#x000b1;&#x0202f;3.1</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x003b3;&#x003b4; T Lymphocytes (cells/&#x003bc;L)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>863&#x0202f;&#x000b1;&#x0202f;176</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">651&#x0202f;&#x000b1;&#x0202f;176</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>640&#x0202f;&#x000b1;&#x0202f;176</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">841&#x0202f;&#x000b1;&#x0202f;176</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>472&#x0202f;&#x000b1;&#x0202f;176</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">750&#x0202f;&#x000b1;&#x0202f;176</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>356&#x0202f;&#x000b1;&#x0202f;176</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">717&#x0202f;&#x000b1;&#x0202f;176</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">634&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">543&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">646&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">532&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">406&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">564&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">432&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">659&#x0202f;&#x000b1;&#x0202f;197</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">408&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">268&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">273&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">377&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">165&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">400&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">261&#x0202f;&#x000b1;&#x0202f;197</td><td align="center" valign="top" rowspan="1" colspan="1">426&#x0202f;&#x000b1;&#x0202f;197</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">&#x003b3;&#x003b4; T WC1<sup>+</sup> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>92.4&#x0202f;&#x000b1;&#x0202f;3.4</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">92.8&#x0202f;&#x000b1;&#x0202f;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">89.6&#x0202f;&#x000b1;&#x0202f;3.4</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>81.2&#x0202f;&#x000b1;&#x0202f;3.4</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">87.8&#x0202f;&#x000b1;&#x0202f;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">91.8&#x0202f;&#x000b1;&#x0202f;3.4</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>80.4&#x0202f;&#x000b1;&#x0202f;3.4</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">87.4&#x0202f;&#x000b1;&#x0202f;3.4</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>90.0&#x0202f;&#x000b1;&#x0202f;3.8</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">91.5&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">85.3&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">83.9&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">85.6&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">89.4&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>74.8&#x0202f;&#x000b1;&#x0202f;3.8</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">88.2&#x0202f;&#x000b1;&#x0202f;3.8</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">89.9&#x0202f;&#x000b1;&#x0202f;3.8<sup>A</sup></td><td align="center" valign="top" rowspan="1" colspan="1">92.2&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">80.6&#x0202f;&#x000b1;&#x0202f;3.8<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">82.7&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">83.1&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">90.3&#x0202f;&#x000b1;&#x0202f;3.8</td><td align="center" valign="top" rowspan="1" colspan="1">81.1&#x0202f;&#x000b1;&#x0202f;3.8<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">88.4&#x0202f;&#x000b1;&#x0202f;3.8</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">B Lymphocytes (cells/&#x003bc;L)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1">0.82&#x0202f;&#x000b1;&#x0202f;0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.67&#x0202f;&#x000b1;&#x0202f;0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.72&#x0202f;&#x000b1;&#x0202f;0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.75&#x0202f;&#x000b1;&#x0202f;0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.67&#x0202f;&#x000b1;&#x0202f;0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.62&#x0202f;&#x000b1;&#x0202f;0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.80&#x0202f;&#x000b1;&#x0202f;0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.99&#x0202f;&#x000b1;&#x0202f;0.17</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">0.79&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.67&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.62&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.60&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.63&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.58&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.84&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.81&#x0202f;&#x000b1;&#x0202f;0.19</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">0.75&#x0202f;&#x000b1;&#x0202f;0.19<sup>A</sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.54&#x0202f;&#x000b1;&#x0202f;0.19<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.58&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.68&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.56&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.52&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.80&#x0202f;&#x000b1;&#x0202f;0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.68&#x0202f;&#x000b1;&#x0202f;0.19</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">B Lymphocytes (%)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1">33.4&#x0202f;&#x000b1;&#x0202f;5.0</td><td align="center" valign="top" rowspan="1" colspan="1">32.3&#x0202f;&#x000b1;&#x0202f;5.0</td><td align="center" valign="top" rowspan="1" colspan="1">30.8&#x0202f;&#x000b1;&#x0202f;5.0</td><td align="center" valign="top" rowspan="1" colspan="1">33.1&#x0202f;&#x000b1;&#x0202f;5.0</td><td align="center" valign="top" rowspan="1" colspan="1">28.5&#x0202f;&#x000b1;&#x0202f;5.0</td><td align="center" valign="top" rowspan="1" colspan="1">37.7&#x0202f;&#x000b1;&#x0202f;5.0</td><td align="center" valign="top" rowspan="1" colspan="1">30.6&#x0202f;&#x000b1;&#x0202f;5.0</td><td align="center" valign="top" rowspan="1" colspan="1">36.5&#x0202f;&#x000b1;&#x0202f;5.0</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">33.6&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">34.0&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">31.7&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">30.9&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">31.2&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">33.1&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">32.9&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">30.0&#x0202f;&#x000b1;&#x0202f;5.6</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">32.5&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">31.4&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">30.8&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">32.2&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">29.4&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">31.1&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">32.1&#x0202f;&#x000b1;&#x0202f;5.6</td><td align="center" valign="top" rowspan="1" colspan="1">27.8&#x0202f;&#x000b1;&#x0202f;5.6</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">CD21<sup>+</sup> B (%)</td><td align="center" valign="top" rowspan="1" colspan="1">CNT</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>93.1&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>A</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">89.3&#x0202f;&#x000b1;&#x0202f;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">89.9&#x0202f;&#x000b1;&#x0202f;2.5</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>86.6&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>86.7&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>87.4&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>87.5&#x0202f;&#x000b1;&#x0202f;2.5</bold>
<sup>
<bold>B</bold>
</sup>
</td><td align="center" valign="top" rowspan="1" colspan="1">91.3&#x0202f;&#x000b1;&#x0202f;2.5</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-1</td><td align="center" valign="top" rowspan="1" colspan="1">92.0&#x0202f;&#x000b1;&#x0202f;2.8<sup>A</sup></td><td align="center" valign="top" rowspan="1" colspan="1">90.0&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">90.8&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">90.2&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">90.8&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">87.6&#x0202f;&#x000b1;&#x0202f;2.8<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">86.8&#x0202f;&#x000b1;&#x0202f;2.8<sup>B</sup></td><td align="center" valign="top" rowspan="1" colspan="1">91.9&#x0202f;&#x000b1;&#x0202f;2.8</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">VAX-2</td><td align="center" valign="top" rowspan="1" colspan="1">91.2&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">88.0&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">90.4&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">86.0&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">90.3&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">89.4&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">87.4&#x0202f;&#x000b1;&#x0202f;2.8</td><td align="center" valign="top" rowspan="1" colspan="1">86.6&#x0202f;&#x000b1;&#x0202f;2.8</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>PCD 0 corresponds to PVD 55; Significant differences between groups at each single timepoint (<sup>a,b</sup>); significant differences between PCD 0 and a single timepoint (<sup>A,B</sup>); <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05. Bold significant differences <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01&#x02013;0.001.</p></table-wrap-foot></table-wrap><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Time-related changes in the absolute count of T lymphocytes <bold>(A)</bold> and the percentage of &#x003b1;&#x003b2; T CD4<sup>+</sup>
<bold>(B)</bold>, &#x003b1;&#x003b2; T CD8<sup>+</sup>
<bold>(C)</bold> and &#x003b3;&#x003b4; T cells <bold>(D)</bold> in vaccinated and unvaccinated buffalo calves after experimental infection with BAHV-1. Significant differences among groups at a single time point (a,b); <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05.</p></caption><graphic xlink:href="fvets-12-1574794-g002" position="float"/></fig></sec></sec><sec sec-type="discussion" id="sec17"><label>4</label><title>Discussion</title><p>The European Union (EU) Animal Health Regulation (<xref rid="ref16" ref-type="bibr">16</xref>) and the EU Delegated Regulation (<xref rid="ref18" ref-type="bibr">18</xref>) have been adopted to ensure that each Member State is officially (fully or partially) free from IBR. In accordance with the Delegated Regulation (EU) 2018/1882, IBR/IPV is listed in categories C, D and E, and <italic>Bubalus ssp</italic>. is a susceptible species. Furthermore, the strategy of differentiating vaccinated from infected animals (also called DIVA) has been implemented (<xref rid="ref18" ref-type="bibr">18</xref>). Based on the serological cross-reactivity of BoAHV-1 and BuAHV-1, we hypothesized that the use of an IBR marker vaccination protocol to immunize cattle against BoAHV-1 would be able to induce protection in water buffaloes following infection with BuAHV-1 (<xref rid="ref19" ref-type="bibr">19</xref>). This hypothesis was tested by evaluating two commercial IBR marker vaccines. The products used for cattle have shown efficacy in reducing the incidence of gE seroconversion in dairy cattle and, consequently, the prevalence in the herd. In addition, they have demonstrated protection against BoAHV-1 infection, including a strong immune response. Furthermore, live or inactivated IBR marker vaccines have demonstrated efficacy in cattle (<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref20" ref-type="bibr">20</xref>).</p><p>The results obtained in this study showed that the vaccines tested caused no clinical signs or adverse reactions. The data from this study are consistent with previously reported studies in cattle and buffalo (<xref rid="ref19" ref-type="bibr">19</xref>, <xref rid="ref22" ref-type="bibr">22&#x02013;24</xref>), suggesting no risk of adverse reactions after vaccine administration using the proposed protocol.</p><p>Rectal temperature remained at normal physiological levels after infection in both groups of vaccinated animals. Furthermore, none of the immunized animals showed any clinical signs of disease throughout the experimental period. In contrast, four control animals showed nasal mucous discharge; one showed a nasal mucous membrane lesion associated with mucous exudate and increased rectal temperatures (39.1&#x000b0;C). These clinical findings differ from Scicluna et al. (<xref rid="ref9" ref-type="bibr">9</xref>), who observed no clinical signs. Two other studies described similar results. In particular, Petrini et al. (<xref rid="ref13" ref-type="bibr">13</xref>) reported rhinorrhea, pseudomembranes, respiratory distress and trapping in 3/5 animals, and Montagnaro et al. (<xref rid="ref21" ref-type="bibr">21</xref>) described rhinorrhea in 5/5 animals.</p><p>Nasal swabs showed positivity by gB real-time PCR in all groups after PCD 2, but for a shorter time in vaccinated animals (up to PCD 7) than in control animals (up to PCD 15). However, these results differ from our previous study (<xref rid="ref13" ref-type="bibr">13</xref>), in which vaccinated animals did not shed the virus used for challenge infection, unlike the control group that shed the virus up to PCD 7 (<xref rid="ref13" ref-type="bibr">13</xref>). These results are probably due to the fact that the animals infected in the present study were younger (6&#x0202f;months) than those infected by Petrini et al. (<xref rid="ref13" ref-type="bibr">13</xref>) (17&#x0202f;months). The age of the water buffaloes used in this study may affect a host&#x02019;s immune response.</p><p>The gB-ELISA and the NA (BuAHV-1-BoAHV-1) were positive for the first time on PVD 14. The same antibodies were observed in the vaccinated group up to the end of the experiment compared to the control group. Studies using modified live vaccines (MLV) or inactivated IBR marker vaccines (gE-) reported similar results (<xref rid="ref21" ref-type="bibr">21</xref>). In addition, the serological results were in line with previous studies in cattle immunized with IBR marker vaccines (gE-) (<xref rid="ref22" ref-type="bibr">22&#x02013;25</xref>). During the vaccination period, immunized water buffaloes showed negative gE-ELISA results. This outcome indicates that BoAHV-1 and BuAHV-1 were not circulating during the experimental period.</p><p>In the present study, we detected gE-ELISA positivity in water buffaloes vaccinated at PCD 63, whereas gE-ELISA seroconversion was observed in the control group at PCD 15. These results obtained in water buffalo are similar to those evidenced in cattle (<xref rid="ref26" ref-type="bibr">26</xref>, <xref rid="ref27" ref-type="bibr">27</xref>). In contrast, no seroconversion in water buffalo following challenge infection was reported by Montagnaro et al. (<xref rid="ref21" ref-type="bibr">21</xref>). The results obtained by Montagnaro et al. may be due to the shorter duration of post-challenge evaluation (15&#x0202f;days), in which the animals may not have had time to become seropositive.</p><p>This study showed that the vaccinated animals shed the virus up to PCD 7, indicating that the vaccination protocol tested did not protect the animals against wt-BuAHV-1 infection. However, the presence of antibody titers detected by VN after vaccination and their subsequent rise after challenge are indicators of possible protection. Reducing challenge virus replication, which should result from the sum of humoral and cellular immune responses, would be the true evidence of protective immunity.</p><p>The differences observed in the immune responses between cattle and buffalo can be attributed to animal genetics, the geographical location of the farm, weather, nutrition, health status of the herd, circulating vaccine strains and viral concentration involved. Furthermore, although the experimental period after the challenge was not very long, it is generally known that the immune response evoked following herpetic infections lasts for months/years. In addition, the serological data obtained in this study are not comparable with those obtained from a possible vaccine registered for the buffalo species; in fact, to date, no vaccine is available on the world market.</p><p>Moreover, this study focuses on the time-related circulatory kinetics of B and T lymphocyte subsets in water buffalo calves induced by vaccination and following BuAHV-1 infection. Lymphocytes are two broad classes of adaptive immune responses: the cell-mediated immune response (T lymphocytes) and the antibody response (B lymphocytes). These populations are the main players in the adaptive immune response to invading viruses and bacteria (<xref rid="ref28" ref-type="bibr">28</xref>). It is known that mammalian T cells are characterized by a T cell receptor (TCR), responsible for recognizing antigens presented by MHC molecules. Despite the cellular immune response to Alphaherpesviruses infection in water buffalo has been poorly investigated, the quantification of lymphocytes and monocyte subsets in peripheral blood during BoAHV-1 and BuAHV-1 infections has been recently performed by flow cytometric analysis (<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref15" ref-type="bibr">15</xref>). Results from this study showed that after the challenge infection with BuAHV-1, all groups experienced a decrease in relative and absolute count of &#x003b1;&#x003b2; T lymphocytes, starting from day 2 until day 10, mainly due to the decrease of &#x003b1;&#x003b2;T CD4<sup>+</sup> subset. However, a sharp decline was observed in unvaccinated water buffaloes, which continued until PCD 63. At this time, lymphopenia was more evident in the control group than in both vaccinated groups. This result is consistent with the reported lymphopenia associated with BoAHV-1 infection in calves (<xref rid="ref29" ref-type="bibr">29</xref>) and in agreement with our previous study (<xref rid="ref13" ref-type="bibr">13</xref>), which showed a recovery of T lymphocytes PCD 63. Eskra et al. (<xref rid="ref30" ref-type="bibr">30</xref>) evidenced that BoAHV-1 selectively infects CD4<sup>+</sup> T cells and, to a lesser extent, CD8<sup>+</sup> T cells, inducing apoptosis and impairing the host immune responses (<xref rid="ref31" ref-type="bibr">31</xref>). Likewise, an increase of CD8<sup>+</sup> T cells was observed in the CNT group at PCD 7 and for all groups at PCD 63. The &#x003b3;&#x003b4; T cells represent 60% of total circulating T lymphocytes in adult ruminants, including cattle (<xref rid="ref32" ref-type="bibr">32</xref>). These subsets of T lymphocytes, activated through TCRs in response to invading pathogens, release cytokines, pro-inflammatory and anti-inflammatory mediators in the framework of a regulatory/suppressive activity reviewed by Righi et al. (<xref rid="ref33" ref-type="bibr">33</xref>). As regards the percentage and total count of &#x003b3;&#x003b4; T cells, for the whole period of infection, higher values were observed in the CNT group compared to both vaccinated groups, with significant differences between groups only at PCDs 2 and 7. Previous studies showed that the quantification of cell subsets in peripheral blood during BoAHV-1 infection was different depending on the vaccination protocol used (<xref rid="ref34" ref-type="bibr">34&#x02013;37</xref>).</p><p>Therefore, the results of the present study suggest paying more attention to the vaccine administration protocol. Finally, regarding the B lymphocyte population, only the CD21<sup>+</sup> subset showed a decreasing trend during the time course of infection in the CNT group. Overall, the flow cytometric results indicated that BuAHV-1 activates the adaptive immune responses, and in addition to the fact that vaccinated and unvaccinated animals showed the same trend throughout the examination period, significant differences were observed on CD4<sup>+</sup>, CD8<sup>+</sup> and &#x003b3;&#x003b4; T cells. Perhaps the use of a vaccine dosage for cattle and not for water buffaloes may have influenced the results. Therefore, further field studies will be needed to evaluate new vaccination protocols for water buffaloes to successfully include a vaccine in the eradication of IBR.</p></sec><sec sec-type="conclusions" id="sec18"><label>5</label><title>Conclusion</title><p>In conclusion, the results of this study allow us to continue the investigation regarding the immune system of the water buffalo species in even greater detail. The results demonstrated that vaccination in the water buffalo species with IBR marker vaccines (gE-/tk-; gE-) authorized in cattle is innocuous and efficacious. The studies conducted in this research are preliminary to a control plan for IBR developed in Italy. In addition, further field studies are needed to evaluate safety and efficacy of these IBR marker vaccines in the water buffalo species on a large scale before their application.</p></sec></body><back><ack><p>The authors are grateful to Gigliola Canepa, University of Milan (Italy), for revising the language of the manuscript. The authors also thank Eleonora Scoccia, Istituto Zooprofilattico Sperimentale Umbria-Marche &#x0201c;Togo Rosati&#x0201d; (Italy), for providing the statistical analysis.</p></ack><sec sec-type="data-availability" id="sec19"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="sec26" ref-type="sec">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="ethics-statement" id="sec20"><title>Ethics statement</title><p>The animal study protocol was approved by the Italian Ministry of Health (Authorization number no. 202/2021-PR). The study was conducted in accordance with the local legislation and institutional requirements.</p></sec><sec sec-type="author-contributions" id="sec21"><title>Author contributions</title><p>GC: Conceptualization, Data curation, Methodology, Resources, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. SP: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. FG: Conceptualization, Data curation, Formal analysis, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. CG: Conceptualization, Data curation, Investigation, Methodology, Supervision, Validation, Writing &#x02013; review &#x00026; editing. ID: Investigation, Writing &#x02013; review &#x00026; editing, Data curation, Formal analysis. FS: Formal analysis, Investigation, Writing &#x02013; review &#x00026; editing. FN: Formal analysis, Investigation, Writing &#x02013; review &#x00026; editing. RV: Data curation, Formal analysis, Investigation, Writing &#x02013; review &#x00026; editing. AB: Conceptualization, Data curation, Investigation, Writing &#x02013; review &#x00026; editing. EC: Conceptualization, Funding acquisition, Resources, Supervision, Visualization, Writing &#x02013; review &#x00026; editing. GM: Conceptualization, Methodology, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. AM: Conceptualization, Data curation, Formal analysis, Funding acquisition, Project administration, Resources, Supervision, Validation, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec23"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec24"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec25"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec26"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fvets.2025.1574794/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fvets.2025.1574794/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data"><label>SUPPLEMENTARY TABLE S1</label><caption><p>Comparison of T and B lymphocytes subset between group of calves unvaccinated (CNT) and vaccinated with two different IBR marker vaccines (VAX-1 and VAX-2) during the time course of vaccination.</p></caption><media xlink:href="Table_1.pdf"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>S</given-names></name><name><surname>Saiano</surname><given-names>K</given-names></name><name><surname>Biondi</surname><given-names>M</given-names></name><name><surname>Ricci</surname><given-names>P</given-names></name><name><surname>Lubritto</surname><given-names>C</given-names></name></person-group>. <article-title>Traceability of 'Mozzarella di Bufala Campana' production chain by means of carbon, nitrogen and oxygen stable isotope ratios</article-title>. <source>J Sci Food Agric</source>. (<year>2020</year>) <volume>100</volume>:<fpage>995</fpage>&#x02013;<lpage>1003</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jsfa.10100</pub-id>, PMID: <pub-id pub-id-type="pmid">31646635</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll1">SND National Database of Istituto Zooprofilattico Sperimentale Dell&#x02019;Abruzzo e del Molise Giuseppe Caporale</collab></person-group>. Dati Forniti dalla BDN Dell&#x02019;anagrafe Zootecnica Istituita dal Ministero della Salute presso il CSN dell&#x02019;Istituto &#x0201c;G. Caporale&#x0201d; di Teramo. (<year>2023</year>). Available online at: <ext-link xlink:href="https://www.vetinfo.it/" ext-link-type="uri">https://www.vetinfo.it/</ext-link> (Accessed 28 September 2023). (In Italian)</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marullo</surname><given-names>A</given-names></name><name><surname>Ciaramella</surname><given-names>R</given-names></name><name><surname>Nocera</surname><given-names>FP</given-names></name><name><surname>Fiorito</surname><given-names>F</given-names></name><name><surname>Montagnaro</surname><given-names>S</given-names></name><name><surname>Pagnini</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Studio preliminare sulla prevalenza di herpesvirus 1, in <italic>Bubalus bubalis</italic>, nella regione Campania</article-title>. <source>J Italian Assoc Buiatr</source>. (<year>2015</year>):<fpage>1</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastoret</surname><given-names>PP</given-names></name><name><surname>Thiry</surname><given-names>E</given-names></name><name><surname>Brochier</surname><given-names>B</given-names></name><name><surname>Derboven</surname><given-names>G</given-names></name></person-group>. <article-title>Bovid herpesvirus 1 infection of cattle: pathogenesis, latency, consequences of latency</article-title>. <source>Ann Rech V&#x000e9;t</source>. (<year>1982</year>) <volume>13</volume>:<fpage>221</fpage>&#x02013;<lpage>35</lpage>. PMID: <pub-id pub-id-type="pmid">6303191</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiry</surname><given-names>E</given-names></name><name><surname>Lemaire</surname><given-names>M</given-names></name><name><surname>Schynts</surname><given-names>F</given-names></name><name><surname>Meyer</surname><given-names>G</given-names></name><name><surname>Dispas</surname><given-names>M</given-names></name><name><surname>Gogev</surname><given-names>S</given-names></name></person-group>. <article-title>Les cons&#x000e9;quences de l&#x02019;infection des bovins par le virus de la rhinotrach&#x000e9;ite infectieuse bovine</article-title>. <source>Point V&#x000e9;t</source>. (<year>1999</year>) <volume>199</volume>:<fpage>279</fpage>&#x02013;<lpage>85</lpage>.</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purpari</surname><given-names>G</given-names></name><name><surname>Alimena</surname><given-names>G</given-names></name><name><surname>Di Marco</surname><given-names>P</given-names></name><name><surname>Cascone</surname><given-names>G</given-names></name><name><surname>Tumino</surname><given-names>G</given-names></name><name><surname>Guercio</surname><given-names>A</given-names></name></person-group>. <article-title>Valutazione della prevalenza di IBR e BVD nella regione Sicilia: modello sperimentale</article-title>. <source>J Ita Assoc Buiatr</source>. (<year>2005</year>) <volume>37</volume>:<fpage>111</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scicluna</surname><given-names>MT</given-names></name><name><surname>Saralli</surname><given-names>G</given-names></name><name><surname>Bruni</surname><given-names>G</given-names></name><name><surname>Sala</surname><given-names>M</given-names></name><name><surname>Cocumelli</surname><given-names>C</given-names></name><name><surname>Caciolo</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Epidemiological situation of herpesvirus infections in buffalo herds: bubaline herpesvirus 1 or bovine herpesvirus 1?</article-title>
<source>Ital J Anim Sci</source>. (<year>2007</year>) <volume>6</volume>:<fpage>845</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.4081/ijas.2007.s2.845</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scicluna</surname><given-names>MT</given-names></name><name><surname>Caprioli</surname><given-names>A</given-names></name><name><surname>Saralli</surname><given-names>G</given-names></name><name><surname>Manna</surname><given-names>G</given-names></name><name><surname>Barone</surname><given-names>A</given-names></name><name><surname>Cersini</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Should the domestic buffalo (<italic>Bubalus bubalis</italic>) be considered in the epidemiology of bovine herpesvirus 1 infection?</article-title>
<source>Vet Microb</source>. (<year>2010</year>) <volume>143</volume>:<fpage>81</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetmic.2010.02.016</pub-id>, PMID: <pub-id pub-id-type="pmid">20206452</pub-id>
</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrini</surname><given-names>S</given-names></name><name><surname>Amoroso</surname><given-names>MG</given-names></name><name><surname>Perugini</surname><given-names>G</given-names></name><name><surname>Gianfelici</surname><given-names>P</given-names></name><name><surname>Corrado</surname><given-names>F</given-names></name><name><surname>Bazzucchi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Rilievo del Bubaline herpesvirus 1 (BuHV-1) in un allevamento di bufali nel centro Italia</article-title>. <source>Large Animals Rev</source>. (<year>2012</year>) <volume>18</volume>:<fpage>113</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheffer</surname><given-names>CM</given-names></name><name><surname>Varela</surname><given-names>APM</given-names></name><name><surname>Teixeira</surname><given-names>TF</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Cibulski</surname><given-names>SP</given-names></name><name><surname>Dos Santos</surname><given-names>HF</given-names></name><etal/></person-group>. <article-title>Neutralizing antibodies to bovine and bubaline alphaherpesviruses in water buffaloes (<italic>Bubalus bubalis</italic>)</article-title>. <source>Braz J Microbiol</source>. (<year>2023</year>) <volume>54</volume>:<fpage>1231</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s42770-023-00930-6</pub-id>, PMID: <pub-id pub-id-type="pmid">36897516</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muylkens</surname><given-names>B</given-names></name><name><surname>Meurens</surname><given-names>F</given-names></name><name><surname>Schynts</surname><given-names>F</given-names></name><name><surname>Farnir</surname><given-names>F</given-names></name><name><surname>Pourchet</surname><given-names>A</given-names></name><name><surname>Bardiau</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Intraspecific bovine herpesvirus 1 recombinants carrying glycoprotein E deletion as a vaccine marker are virulent in cattle</article-title>. <source>J Gen Virol</source>. (<year>2006</year>) <volume>87</volume>:<fpage>2149</fpage>&#x02013;<lpage>54</lpage>. doi: <pub-id pub-id-type="doi">10.1099/vir.0.81969-0</pub-id>, PMID: <pub-id pub-id-type="pmid">16847110</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>LJ</given-names></name><name><surname>Muench</surname><given-names>HA</given-names></name></person-group>. <article-title>A simple method for estimating 50% end points</article-title>. <source>Am J Hyg</source>. (<year>1933</year>) <volume>27</volume>:<fpage>493</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrini</surname><given-names>S</given-names></name><name><surname>Martucciello</surname><given-names>A</given-names></name><name><surname>Grandoni</surname><given-names>F</given-names></name><name><surname>De Matteis</surname><given-names>G</given-names></name><name><surname>Cappelli</surname><given-names>G</given-names></name><name><surname>Giammarioli</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Evaluation of safety and efficacy of an inactivated marker vaccine against bovine alphaherpesvirus 1 (BoHV-1) in water Buffalo (<italic>Bubalus bubalis</italic>)</article-title>. <source>Vaccines</source>. (<year>2021</year>) <volume>9</volume>:<fpage>355</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9040355</pub-id>, PMID: <pub-id pub-id-type="pmid">33917160</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab id="coll2">OIE</collab></person-group>. <source>OIE Manual of Standards for Diagnostic Tests Vaccines. Infectious bovine rhinotracheitis/infectious pustular vulvovaginitis</source>. (<year>2010</year>). <publisher-loc>Paris</publisher-loc>: <publisher-name>OIE</publisher-name>, pp. <fpage>1</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandoni</surname><given-names>F</given-names></name><name><surname>Hussen</surname><given-names>J</given-names></name><name><surname>Signorelli</surname><given-names>F</given-names></name><name><surname>Napolitano</surname><given-names>F</given-names></name><name><surname>Scat&#x000e0;</surname><given-names>MC</given-names></name><name><surname>De Donato</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Evaluation of hematological profiles and monocyte subpopulations in water Buffalo calves after immunization with two different IBR marker vaccines and subsequent infection with bubaline alphaherpesvirus-1</article-title>. <source>Vaccine</source>. (<year>2023</year>) <volume>11</volume>:<fpage>1405</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines11091405</pub-id>, PMID: <pub-id pub-id-type="pmid">37766082</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>M</given-names></name><name><surname>Hennis-Plasschaert</surname><given-names>JA</given-names></name></person-group>. <article-title>Regulation (EU) 2016/429 of the European Parliament and of the council of 9 march 2016, on transmissible animal diseases and amending and repealing certain acts in the area of animal health (animal health law)</article-title>. <source>Off J Eur Union</source>. (<year>2016</year>) <volume>84</volume>:<fpage>1</fpage>&#x02013;<lpage>208</lpage>.</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juncker</surname><given-names>J-C</given-names></name></person-group>. <article-title>Commission delegated regulation (EU) 2018/1629 of 25 July 2018, amending the list of diseases set out in annex II to regulation (EU) 2016/429 of the European Parliament and of the council on transmissible animal diseases and amending and repealing certain acts in the area of animal health (animal health law)</article-title>. <source>Off J Eur Union</source>. (<year>2018</year>) <volume>272</volume>:<fpage>1</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juncker</surname><given-names>J-C</given-names></name></person-group>. <article-title>Commission implementing regulation (EU) 2018/1882 of 3 December 2018, on the application of certain disease prevention and control rules to categories of listed diseases and establishing a list of species and groups of species posing a considerable risk for the spread of these diseases</article-title>. <source>Off J Eur Union</source>. (<year>2018</year>) <volume>308</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>HI</given-names></name><name><surname>Rabbani</surname><given-names>M</given-names></name><name><surname>Awan</surname><given-names>FN</given-names></name><name><surname>Raza</surname><given-names>S</given-names></name><name><surname>Faryal</surname><given-names>S</given-names></name><name><surname>Azeem</surname><given-names>S</given-names></name></person-group>. <article-title>The immunogenicity and efficacy of acommercially available infectious bovine Rhinotracheitis (IBR) virus vaccine against a Pakistani field IBR strain</article-title>. <source>Vet Ital</source>. (<year>2023</year>) <volume>59</volume>:<fpage>65</fpage>&#x02013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.12834/VetIt.2922.19929.3</pub-id>, PMID: <pub-id pub-id-type="pmid">37994637</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muratore</surname><given-names>E</given-names></name><name><surname>Bertolotti</surname><given-names>L</given-names></name><name><surname>Nogarol</surname><given-names>C</given-names></name><name><surname>Caruso</surname><given-names>C</given-names></name><name><surname>Lucchese</surname><given-names>L</given-names></name><name><surname>Lotti</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Surveillance of infectious bovine Rhinotracheitis in marker-vaccinated dairy herds: application of a recombinant gE ELISA on bulk milk samples</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>2017</year>) <volume>185</volume>:<fpage>1</fpage>&#x02013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetimm.2017.01.003</pub-id><pub-id pub-id-type="pmid">28241997</pub-id>
</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagnaro</surname><given-names>S</given-names></name><name><surname>De Martinis</surname><given-names>C</given-names></name><name><surname>Iovane</surname><given-names>V</given-names></name><name><surname>Ciarcia</surname><given-names>R</given-names></name><name><surname>Damiano</surname><given-names>S</given-names></name><name><surname>Nizza</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Bovine herpesvirus type 1 marker vaccine induces cross-protection against bubaline herpesvirus type 1 in water buffalo</article-title>. <source>Prev Vet Med</source>. (<year>2014</year>) <volume>116</volume>:<fpage>56</fpage>&#x02013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.prevetmed.2014.06.002</pub-id><pub-id pub-id-type="pmid">24985155</pub-id>
</mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martini</surname><given-names>V</given-names></name><name><surname>Bernardi</surname><given-names>S</given-names></name><name><surname>Russo</surname><given-names>V</given-names></name><name><surname>Guccione</surname><given-names>J</given-names></name><name><surname>Comazzi</surname><given-names>S</given-names></name><name><surname>Roperto</surname><given-names>S</given-names></name></person-group>. <article-title>Blood lymphocyte subpopulations in healthy water buffaloes (<italic>Bubalus bubalis</italic>, Mediterranean lineage): reference intervals and influence of age and reproductive history</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>2019</year>) <volume>211</volume>:<fpage>58</fpage>&#x02013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetimm.2019.04.007</pub-id>, PMID: <pub-id pub-id-type="pmid">31084895</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castrucci</surname><given-names>G</given-names></name><name><surname>Frigeri</surname><given-names>F</given-names></name><name><surname>Salvatori</surname><given-names>D</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><name><surname>Sardonini</surname><given-names>Q</given-names></name><name><surname>Cassai</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Vaccination of calves against bovine herpesvirus-1: assessment of the protective value of eight vaccines</article-title>. <source>Comp Immunol Microbiol Infect</source>. (<year>2002</year>) <volume>25</volume>:<fpage>29</fpage>&#x02013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0147-9571(01)00017-0</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clinton</surname><given-names>J</given-names></name></person-group>. <article-title>Bovine herpesvirus 1 counteracts immune responses and immune-surveillance to enhance pathogenesis and virus transmission</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<fpage>1008</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.01008</pub-id><pub-id pub-id-type="pmid">31134079</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>JC</given-names></name><name><surname>de Jong</surname><given-names>MCM</given-names></name><name><surname>Franken</surname><given-names>P</given-names></name><name><surname>Frankena</surname><given-names>K</given-names></name><name><surname>Hage</surname><given-names>JJ</given-names></name><name><surname>Kaashoek</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>An inactivated gE-negative marker vaccine and an experimental gD-subunit vaccine reduce the incidence of bovine herpesvirus 1 infections in the field</article-title>. <source>Vaccine</source>. (<year>1998</year>) <volume>16</volume>:<fpage>265</fpage>&#x02013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0264-410X(97)00166-7</pub-id>, PMID: <pub-id pub-id-type="pmid">9607041</pub-id>
</mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>JC</given-names></name><name><surname>Kaashoek</surname><given-names>MJ</given-names></name><name><surname>van Oirschot</surname><given-names>JT</given-names></name></person-group>. <article-title>Inactivated bovine herpesvirus 1 marker vaccines are more efficacious in reducing virus excretion after reactivation than a live marker vaccine</article-title>. <source>Vaccine</source>. (<year>1997</year>) <volume>15</volume>:<fpage>1512</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0264-410X(97)00092-3</pub-id>, PMID: <pub-id pub-id-type="pmid">9330461</pub-id>
</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrini</surname><given-names>S</given-names></name><name><surname>Martucciello</surname><given-names>A</given-names></name><name><surname>Righi</surname><given-names>C</given-names></name><name><surname>Cappelli</surname><given-names>G</given-names></name><name><surname>Torresi</surname><given-names>C</given-names></name><name><surname>Grassi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Assessment of different infectious bovine Rhinotracheitis marker vaccines in calves</article-title>. <source>Vaccine</source>. (<year>2022</year>) <volume>10</volume>:<fpage>1204</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines10081204</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Raff</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>K</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name></person-group>. <source>Molecular biology of the cell</source>. <edition>4th</edition> ed. <publisher-loc>New York</publisher-loc>: <publisher-name>Garland Science</publisher-name> (<year>2002</year>).</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griebel</surname><given-names>PJ</given-names></name><name><surname>Ohmann</surname><given-names>HB</given-names></name><name><surname>Lawman</surname><given-names>MJ</given-names></name><name><surname>Babiuk</surname><given-names>LA</given-names></name></person-group>. <article-title>The interaction between bovine herpesvirus type 1 and activated bovine T lymphocytes</article-title>. <source>J Gen Virol</source>. (<year>1990</year>) <volume>71</volume>:<fpage>369</fpage>&#x02013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1099/0022-1317-71-2-369</pub-id><pub-id pub-id-type="pmid">2155290</pub-id>
</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskra</surname><given-names>L</given-names></name><name><surname>Splitter</surname><given-names>GA</given-names></name></person-group>. <article-title>Bovine herpesvirus-1 infects activated CD4+ lymphocytes</article-title>. <source>J Gen Virol</source>. (<year>1997</year>) <volume>78</volume>:<fpage>2159</fpage>&#x02013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1099/0022-1317-78-9-2159</pub-id><pub-id pub-id-type="pmid">9292002</pub-id>
</mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levings</surname><given-names>RL</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name></person-group>. <article-title>Immunity to bovine herpesvirus 1: II. Adaptive immunity and vaccinology</article-title>. <source>Anim Health Res Rev</source>. (<year>2013</year>) <volume>14</volume>:<fpage>103</fpage>&#x02013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S1466252313000054</pub-id>, PMID: <pub-id pub-id-type="pmid">23800430</pub-id>
</mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>WC</given-names></name><name><surname>Brown</surname><given-names>WC</given-names></name><name><surname>Hamilton</surname><given-names>MJ</given-names></name><name><surname>Wyatt</surname><given-names>CR</given-names></name><name><surname>Orden</surname><given-names>CR</given-names></name><name><surname>Khalid</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Analysis of monoclonal antibodies specific for the gamma delta TcR</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>1996</year>) <volume>52</volume>:<fpage>275</fpage>&#x02013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0165-2427(96)05578-X</pub-id><pub-id pub-id-type="pmid">8896216</pub-id>
</mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Righi</surname><given-names>C</given-names></name><name><surname>Franzoni</surname><given-names>G</given-names></name><name><surname>Feliziani</surname><given-names>F</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Petrini</surname><given-names>S</given-names></name></person-group>. <article-title>The cell-mediated immune response against bovine alphaherpesvirus 1 (BoHV-1) infection and vaccination</article-title>. <source>Vaccines</source>. (<year>2023</year>) <volume>11</volume>:<fpage>785</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines11040785</pub-id>, PMID: <pub-id pub-id-type="pmid">37112697</pub-id>
</mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>V</given-names></name><name><surname>Risalde</surname><given-names>MA</given-names></name><name><surname>S&#x000e1;nchez-Cord&#x000f3;n</surname><given-names>PJ</given-names></name><name><surname>Pedrera</surname><given-names>M</given-names></name><name><surname>Romero-Palomo</surname><given-names>F</given-names></name><name><surname>Luzzago</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effect of infection with BHV-1 on peripheral blood leukocytes and lymphocyte subpopulations in calves with subclinical BVD</article-title>. <source>Res Vet Sci</source>. (<year>2013</year>) <volume>95</volume>:<fpage>115</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.rvsc.2013.02.018</pub-id>, PMID: <pub-id pub-id-type="pmid">23541923</pub-id>
</mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risalde</surname><given-names>MA</given-names></name><name><surname>Molina</surname><given-names>V</given-names></name><name><surname>S&#x000e1;nchez-Cord&#x000f3;n</surname><given-names>PJ</given-names></name><name><surname>Romero-Palomo</surname><given-names>F</given-names></name><name><surname>Pedrera</surname><given-names>M</given-names></name><name><surname>G&#x000f3;mez-Villamandos</surname><given-names>JC</given-names></name></person-group>. <article-title>Effects of pre infection with bovine viral diarrhea virus on immune cells from the lungs of calves inoculated with bovine herpesvirus 1.1</article-title>. <source>Vet Pathol</source>. (<year>2015</year>) <volume>52</volume>:<fpage>644</fpage>&#x02013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0300985814551579</pub-id>, PMID: <pub-id pub-id-type="pmid">25322747</pub-id>
</mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Al-Haidari</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>T cell receptor (TCR) signaling in health and disease</article-title>. <source>Sig Transduct Target Ther</source>. (<year>2021</year>) <volume>6</volume>:<fpage>412</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-021-00823-w</pub-id>, PMID: <pub-id pub-id-type="pmid">34897277</pub-id>
</mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>SC</given-names></name></person-group>. <article-title>Vaccine applications of flow cytometry</article-title>. <source>Methods</source>. (<year>2012</year>) <volume>57</volume>:<fpage>383</fpage>&#x02013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ymeth.2012.01.001</pub-id><pub-id pub-id-type="pmid">22251671</pub-id>
</mixed-citation></ref></ref-list></back></article>